T he obesity epidemic has led to a marked increase in the incidence of type 2 diabetes mellitus, metabolic syndrome, and systemic hypertension. When present, these comorbidities contribute to the adverse cardiovascular outcomes that have been associated with obesity. In fact, for overweight individuals, the hazard ratio for cardiovascular mortality has been reported to be 1.4 to 2.8 (stratified by increasing body mass index) during 10 to 26 years of follow-up. 1 This excess cardiovascular risk seems to be confined to obese individuals with coronary heart disease risk factors, particularly systemic hypertension. A recent landmark study of the Framingham Offspring cohort demonstrated convincingly that arterial stiffness, a vascular pathophenotype characterized by progressive stiffening of large conduit vessels that perturbs blood flow patterns in the distal vasculature, precedes increases in systolic blood pressure and incident hypertension. 2 Other studies have established that arterial stiffness is present in individuals with obesity or metabolic syndrome and can predict future cardiovascular events. 3 In some cases, weight reduction has been shown to decrease arterial stiffness, in part, through the loss of total body and abdominal adiposity, suggesting that vascular stiffness may be reversible. 1 Thus, arterial distensibility may be considered as a measure of vascular health, and progression to arterial stiffening may be viewed as a biomarker to predict future cardiovascular events. 4 Although epidemiological studies highlight the association between obesity, arterial stiffness, and hypertension, they are unable to inform on causality, particularly at a cellular or molecular level. To date, there have been few mechanistic studies examining the pathogenesis of arterial stiffness in obesity using models that recapitulate the phenomenon as it occurs in humans: high-fat, high-sugar caloric excess. In this issue of Hypertension, Weisbrod et al 5 provide some of the first longawaited evidence to demonstrate that obesity induces arterial stiffness through several complementary mechanisms, including inflammation, endothelial dysfunction, and extracellular matrix remodeling, to affect both vascular structure and function. Using a high-fat-, high-sucrose-fed mouse model of obesity and metabolic syndrome, they were also able to show that weight gain and metabolic derangements occur before or concomitant with arterial stiffening and that arterial stiffness is reversible with a return to a normal caloric dietary and weight loss. 5 The finding that inflammation and endothelial dysfunction are contributors to obesity-induced arterial stiffness is not surprising given their role in vascular dysfunction. There was infiltration of perivisceral adipose tissue with activated macrophages as well as elevated vascular expression of proinflammatory cytokines. There was also evidence of endothelial dysfunction and impaired vascular reactivity, indicating a decrease in bioavailable NO, as well as an increase in vascular oxidant stress as shown by oxidative post-translational modification of sarco/endoplasmic reticulum Ca 2+ -ATPase. 5 In addition to favoring vasoconstriction, these processes initiate vascular remodeling by stimulating cell proliferation, migration, hypertrophy, or extracellular matrix modification. There was vascular remodeling in obese mice, which developed aortic medial hypertrophy; however, this finding was not attributable to an increase in collagen deposition and was not reversible by diet. Although the cause of the aortic hypertrophy remains unclear, it is evident that this alone did not account for the observed arterial stiffening. Instead, there was evidence of extracellular matrix remodeling as demonstrated by the increase in activity of transglutaminase-2, which is NO sensitive and increases extracellular matrix cross-linking. 5 Therefore, the mechanisms underlying arterial stiffness in this model seem to be related and may be codependent.
The findings from this study are in concert with prior works that have explored putative mechanisms to explain arterial stiffness related to other disease states (Figure) . Extracellular matrix remodeling that influences the integrity of collagen, elastin, or other components may contribute to vascular rigidity. For example, matrix metalloproteinase(s) activation promotes elastin cleavage and release of proinflammatory fragments that increase vascular stiffness. 6 Extracellular matrix glycosaminoglycans can lose their viscoelastic properties, whereas changes to fibronectin or integrin expression may increase stiffness by firming attachment of vascular smooth muscle cells to the extracellular matrix. Increased vascular rigidity may also be explained by the deposition of circulating calcific microparticles or the in situ formation of vascular microcalcifications. 7 Other studies have focused on the contributions of different cell types to arterial stiffness. Vascular smooth muscle cells themselves may become rigid, and atomic force microscopy of cells isolated from hypertensive models has found an increase in cell membrane stiffness, similar to what was observed in
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the present study. 6 This may occur as a result of mineralocorticoid receptor activation, which increases cellular water content and stiffness although short-term receptor blockade failed to improve vascular rigidity, suggesting that the timing of this intervention may be important. 6, 8 Another possible mechanism is that of increased vascular cell endoplasmic reticulum stress, which would promote vascular cell stiffness by increasing the burden of aged and dysfunctional proteins and organelles in the cells. 6 Owing to their role in hypertension, T cells have been proposed to mediate arterial stiffness, and studies have linked interferon-γ and interleukin-6 to a loss of arterial distensibility. 6 Adipocytes and adipokines have also been associated with arterial stiffening, and the present study suggests an interaction between these mediators and vascular cells. 9 Obesity or its associated metabolic abnormalities may also initiate genetic or epigenetic changes that favor arterial stiffening. Arterial stiffness has been shown to be heritable, and a genome-wide association study of 9 European ancestry cohorts identified a locus in the 3′-BCL11B gene desert on chromosome 14 that was associated with arterial stiffness. It was presumed that this area contained gene enhancers, regulatory elements, or microRNAs that regulate factors to modulate stiffness. 10 Although not investigated directly in the present study, future gene profiling from animal models of arterial stiffness may identify a cluster of coregulated genes localized to this area.
Perhaps the most intriguing finding from the current study is that weight loss and decreased adiposity improved arterial stiffness. With weight loss, indices of inflammation, endothelial dysfunction, and extracellular matrix remodeling returned to baseline preobesity levels. These changes occurred in association with an improvement in metabolic parameters, and therefore, identifying a single responsible mediator may be difficult. It is, however, interesting to consider that weight loss alone might be as efficacious as pharmacological interventions aimed at improving vascular function and decreasing arterial stiffness. In future studies, it will be of importance to determine whether or not there is a remodeling threshold for the reversal of arterial stiffness beyond which diet alone will not be effective. Findings from this and other similar mechanistic studies will help to establish additional genetic, biochemical, and structural remodeling processes that modulate obesityrelated arterial stiffness and determine whether diet alone or in combination with other pharmacotherapies is sufficient to ameliorate arterial stiffness.
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